Illumina (NASDAQ:ILMN) Rating Increased to Outperform at Daiwa Securities Group

Illumina (NASDAQ:ILMN) was upgraded by equities research analysts at Daiwa Securities Group from a “neutral” rating to an “outperform” rating in a research note issued on Thursday. The firm currently has a $155.00 target price on the life sciences company’s stock. Daiwa Securities Group’s price objective suggests a potential upside of 6.90% from the stock’s current price.

ILMN has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. UBS Group restated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Stifel Nicolaus raised their price objective on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Canaccord Genuity Group dropped their price target on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Finally, Piper Sandler dropped their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $134.88.

Illumina Stock Performance

NASDAQ ILMN opened at $145.00 on Thursday. Illumina has a 12-month low of $77.50 and a 12-month high of $155.53. The company has a market cap of $21.94 billion, a P/E ratio of 26.36, a PEG ratio of 2.41 and a beta of 1.42. The company has a fifty day simple moving average of $128.03 and a 200 day simple moving average of $129.13. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.97 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts predict that Illumina will post 5.2 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

Several hedge funds have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB boosted its position in shares of Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the last quarter. Meeder Advisory Services Inc. increased its position in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank raised its stake in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.